If you want to understand where American healthcare, advertising, and culture are colliding in real time, you could do worse than watching the Super Bowl. For decades, the game’s commercials have been a mirror of American priorities, from beer and cars to dotcoms and smartphones. Over the past decade, prescription drug companies have increasingly muscled their way into the field. What used to be an occasional novelty has become a full-blown marketing strategy, with pharmaceutical giants paying top dollar to pitch treatments to more than 100 million viewers at once.

In an environment where figures like Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. have helped spark broader public reflection on health and wellness, it’s perhaps not surprising that advertising in this space has drawn a bit more regulatory attention. Last year, some companies promoting health products during the Super Bowl received inquiries from the Food and Drug Administration (FDA) about whether their ads provided enough medical context alongside their promotional appeal.

The conversation was less about the act of advertising itself and more about presentation. When potential risks and side effects are not communicated as clearly as benefits, consumers may not always get the fullest picture. In healthcare, a fuller context can be helpful as people weigh personal medical choices.

This is where the FDA’s renewed focus on direct-to-consumer drug advertising matters. Under Commissioner Marty Makary, the agency has........

© Townhall